CBD石油有什麼幫助？

FDA選擇宣佈於26年2018月XNUMX日（即國際禁止藥物濫用日）批准GW Pharmaceuticals的Epidiolex（cannabidiol）口服液的市場准入。 The drug is approved for the treatment of rare and severe epilepsy, Dravet syndrome and Lennox-Gastaut syndrome.該藥被批准用於治療罕見和嚴重的癲癇，Dravet綜合徵和Lennox-Gastaut綜合徵。
Currently, this is the first new drug approved by the FDA to be marketed with purified cannabis extract.當前，這是FDA批准的第一種與純化的大麻提取物一起銷售的新藥。 Its ingredient is purified cannabidiol (CBD), a cannabinoid with no euphoria side effects.它的成分是純化的大麻二酚（CBD），一種沒有興奮感副作用的大麻素。 It won't bring the nerve stimulation effect caused by tetrahydrocannabinol (THC).它不會帶來四氫大麻酚（THC）引起的神經刺激作用。 Its potential to treat epilepsy was validated in three randomized, double-blind, placebo-controlled clinical trials.在三項隨機，雙盲，安慰劑對照的臨床試驗中證實了其治療癲癇的潛力。 In early January this year, the positive results in phase III clinical trial of the cannabinoid Epidiolex (cannabidiol) was published in Lancet, an authoritative medical journal.今年XNUMX月初，權威醫學雜誌《柳葉刀》發表了大麻素Epidiolex（cannabidiol）的III期臨床試驗的陽性結果。 This new drug has been awarded the FDA-issued fast-track qualification (for Dravet syndrome) and orphan drug qualification (for both epilepsies).該新藥已獲得FDA頒發的快速通道認證（針對Dravet綜合徵）和孤兒藥物認證（針對兩種癲癇症）。 After its listing application was accepted, the US FDA also granted its priority for assessment.在其上市申請被接受之後，美國FDA也授予了其優先評估權。 The approval for its listing is a recognition of therapeutic potential of this new drug, and it is also the first treatment to be approved for Dravet syndrome.批准上市是對這種新藥治療潛力的認可，也是第一種被批准用於Dravet綜合徵的療法。
Hemp naturally grows in the northern hemisphere, which adapts to various climates, with no need to require artificial cultivation, has a growth cycle of 108-120 days, and its THC content is less than 0.3%.大麻在北半球自然生長，適應各種氣候，無需人工栽培，生長周期為XNUMX-XNUMX天，四氫大麻酚含量低於XNUMX％。 Interestingly, CBD competes with THC, while CBD can hinder the impact of THC on the human nervous system.有趣的是，CBD與THC競爭，而CBD可以阻礙THC對人類神經系統的影響。 Therefore, CBD has obtained the nickname of “anti-marijuana compound”.因此，生物多樣性公約獲得了“反大麻化合物”的綽號。

說到麻油的好處，它通常指的是 CBD油。 Although more research is still needed on儘管仍然需要更多的研究 CBD油，現有研究和臨床證據為我們提供了一些線索：
1.癲癇病
A recent retrospective study in Israel showed that epileptic seizures were significantly reduced with medical cannabis of high CBD content.以色列最近的一項回顧性研究表明，高CBD含量的醫用大麻可顯著減少癲癇發作。 In this study, 52% of patients had at least a 50% reduction in seizures.在這項研究中，XNUMX％的患者癲癇發作減少了至少XNUMX％。 
2.焦慮
根據2011年的一項研究，研究人員發現 CBD油 與安慰劑相比，焦慮和認知障礙明顯減少。
3.緩解疼痛
Some animal studies have shown that topical use of cannabis oil can improve pain and inflammation.一些動物研究表明，局部使用大麻油可改善疼痛和炎症。 However, most of the data presented showed the most effective analgesic combination is CBD and THC.但是，大多數數據顯示最有效的止痛藥組合是CBD和THC。 
4.阿爾茨海默氏病
2014年的一項小規模研究表明，CBD油可預防阿爾茨海默氏病的常見症狀，但需要更多的研究來驗證這些發現。
5.用作抗氧化劑
這意味著它可以保護您的身體免受自由基的傷害，而CBD也被認為具有抗抑鬱，抗噁心，保護腸道和平衡免疫系統的作用。